According to data from the New York City Department of Health (NYC DOH) in the United States, the local authority first reported a cluster of Legionellosis cases on July 25. As of August 15 (local time), there have been 101 confirmed cases and 4 deaths.
Legionellosis is a respiratory disease caused by infection with Legionella pneumophila. It is mainly transmitted through the respiratory tract, with aerosol transmission being the most common route—for example, via air conditioning cooling towers, hot and cold water supply systems, and humidifiers.
During hot summer months, with the prolonged use of air conditioners, Legionella pneumophila quietly enters its active phase. The susceptible population is mainly middle-aged and elderly men who smoke or have chronic diseases.
The clinical manifestations of legionellosis include fever, chills, muscle aches, and cough; some patients may also experience dyspnea. These symptoms typically last for 2–5 days. The incubation period of this bacterium ranges from 2 to 10 days (with a maximum of 2 weeks). Once diagnosed, legionellosis can be treated with antibiotics, with first-line drugs including erythromycin, azithromycin, and clarithromycin.
Currently, there are no vaccines or medications available to prevent legionellosis. Therefore, accurate detection and rapid traceability have become the top priorities for epidemic prevention and control. iGeneTech’s Legionella pneumophila Whole-Genome Capture Kit builds a defense line based on “full pathogen coverage + high-precision detection,” making every test the first line of defense for health protection.
Based on the independently developed intellectual property rights of TargetSeq® Liquid-Phase Probe Hybrid Capture Technology, the kit is designed with 393,040 specific probes, using multiple strain sequences from the NCBI database as references. Its coverage rate reaches 99.99%, ensuring no missed detection of Legionella pneumophila strains.
Probe Data Indicators
Product Advantages
l Whole-genome coverage, covering all strains in a single test;
l Magnetic bead-based extraction + automated workstation, reducing human error;
l Self-developed products for the entire workflow, no additional adaptation required.
Worry-Free Full-Process Testing
The Pathogenic Microorganism Whole-Genome Capture Kit has sufficient stock. Paired with the magnetic bead-based extraction kit and DNA pathogen library construction & capture kit, it enables seamless connection from samples to data. It supports batch processing with automated liquid handling workstations, capable of processing 96 samples per batch to meet large-scale screening needs. Additionally, it is compatible with a variety of high-throughput sequencing platforms to satisfy requirements of different scenarios.
CN
